Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant ovarian ablation and tamoxifen with or without anthracycline-cyclophosphamide chemotherapy in premenopausal hormone receptor-positive node-positive breast cancer
ACTRN12606000534583Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Jul 1993
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, doxorubicin, epirubicin, cyclophosphamide and goserelin in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoints: Overall survival, Disease-free survival and 1 more. Started Jul 1993; status: completed.
02
Drugs
tamoxifendoxorubicinepirubicincyclophosphamidegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000534583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000534583.